Omeros (STU:3O8) E10: €-1.02 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3O8 Omeros Corp STU:3O8
33 GF Score
Price €16.50
! 6 Warning Signs
View Full Analysis

What is Omeros E10?

Omeros STU:3O8 +3.13% 33 E10 is €-1.02 as of Jun. 2026. GuruFocus rates STU:3O8 with a GF Score™ of 33/100. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Omeros's adjusted earnings per share data for the three months ended in Jun. 2026 was €0.130. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.02 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 2.60% per year. During the past 5 years, the average E10 Growth Rate was 5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Omeros was 10.80% per year. The lowest was 2.10% per year. And the median was 7.90% per year.

As of today (2026-08-22), Omeros's current stock price is €16.50. Omeros's E10 for the quarter that ended in Jun. 2026 was €-1.02. Omeros's Shiller PE Ratio of today is .


Omeros  (STU:3O8) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Omeros E10 Related Terms


Omeros E10 Historical Data

* Premium members only.

The historical data trend for Omeros's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omeros E10 Chart

Omeros Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.47 -1.28 -1.43 -1.71 -1.04

Omeros Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 -1.28 -1.04 -1.04 -1.02

STU:3O8 vs STTK, BBOT, XOMA: E10 Comparison

For the Biotechnology subindustry, Omeros's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Omeros's Shiller PE Ratio falls into.


STU:3O8
33GF Score
Omeros Corp STU:3O8
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omeros E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Omeros's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.13/333.9520*333.9520
=0.130

Current CPI (Jun. 2026) = 333.9520.

Omeros Quarterly Data

per share eps CPI Adj_EPS
201609 -0.303 241.428 -0.419
201612 -0.427 241.432 -0.591
201703 -0.318 243.801 -0.436
201706 -0.294 244.955 -0.401
201709 -0.134 246.819 -0.181
201712 -0.287 246.524 -0.389
201803 -0.503 249.554 -0.673
201806 -0.599 251.989 -0.794
201809 -0.694 252.439 -0.918
201812 -0.422 251.233 -0.561
201903 -0.443 254.202 -0.582
201906 -0.257 256.143 -0.335
201909 -0.300 256.759 -0.390
201912 -0.522 256.974 -0.678
202003 -0.480 258.115 -0.621
202006 -0.542 257.797 -0.702
202009 -0.560 260.280 -0.719
202012 -0.493 260.474 -0.632
202103 -0.479 264.877 -0.604
202106 -0.382 271.696 -0.470
202109 -0.306 274.310 -0.373
202112 3.965 278.802 4.749
202203 -0.481 287.504 -0.559
202206 -0.464 296.311 -0.523
202209 -0.283 296.808 -0.318
202212 1.935 296.797 2.177
202303 -0.504 301.836 -0.558
202306 -0.545 305.109 -0.597
202309 -0.562 307.789 -0.610
202312 -0.138 306.746 -0.150
202403 -0.580 312.332 -0.620
202406 -0.901 314.175 -0.958
202409 -0.505 315.301 -0.535
202412 -0.516 315.605 -0.546
202503 -0.536 319.799 -0.560
202506 -0.373 322.561 -0.386
202509 -0.400 324.800 -0.411
202512 0.837 324.054 0.863
202603 0.536 330.213 0.542
202606 0.130 333.952 0.130

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.02 mean?
Omeros (STU:3O8) has a E10 of €-1.02 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Omeros and its competitors.
Is Omeros' E10 too high?
Omeros' current E10 is €-1.02. Overall, Omeros has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Omeros' E10 compare to STTK and BBOT?
Omeros' E10 of €-1.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Omeros and its competitors. Omeros's current E10 is €-1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omeros stock overvalued right now?
Omeros (STU:3O8) has a current E10 of €-1.02. The current E10 is €-1.02. Omeros' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Omeros (STU:3O8), the current E10 is €-1.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omeros Business Description

Other Exchanges OMER:USA0KBU:UK
Address 201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
33GF Score

Get the complete analysis for STU:3O8

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.50
Price